These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17095020)

  • 1. Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus.
    Zurakowski R; Wodarz D
    J Theor Biol; 2007 Mar; 245(1):1-8. PubMed ID: 17095020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition.
    Bagheri N; Shiina M; Lauffenburger DA; Korn WM
    PLoS Comput Biol; 2011 Feb; 7(2):e1001085. PubMed ID: 21379332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells.
    Anders M; Christian C; McMahon M; McCormick F; Korn WM
    Cancer Res; 2003 May; 63(9):2088-95. PubMed ID: 12727824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetically modified adenoviruses against gliomas: from bench to bedside.
    Gomez-Manzano C; Yung WK; Alemany R; Fueyo J
    Neurology; 2004 Aug; 63(3):418-26. PubMed ID: 15304571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.
    O'Shea CC; Johnson L; Bagus B; Choi S; Nicholas C; Shen A; Boyle L; Pandey K; Soria C; Kunich J; Shen Y; Habets G; Ginzinger D; McCormick F
    Cancer Cell; 2004 Dec; 6(6):611-23. PubMed ID: 15607965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
    Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
    Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current developments in adenovirus-based cancer gene therapy.
    Rein DT; Breidenbach M; Curiel DT
    Future Oncol; 2006 Feb; 2(1):137-43. PubMed ID: 16556080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: a novel antitumor approach.
    Jiang G; Xin Y; Zheng JN; Liu YQ
    Int J Cancer; 2011 Jul; 129(2):263-74. PubMed ID: 21509783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy.
    Hensen LCM; Hoeben RC; Bots STF
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ONYX-015. Onyx Pharmaceuticals.
    Cohen EE; Rudin CM
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1770-5. PubMed ID: 11892945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coxsackie and adenovirus receptor binding ablation reduces adenovirus liver tropism and toxicity.
    Yun CO; Yoon AR; Yoo JY; Kim H; Kim M; Ha T; Kim GE; Kim H; Kim JH
    Hum Gene Ther; 2005 Feb; 16(2):248-61. PubMed ID: 15761264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor.
    Fechner H; Pinkert S; Wang X; Sipo I; Suckau L; Kurreck J; Dörner A; Sollerbrant K; Zeichhardt H; Grunert HP; Vetter R; Schultheiss HP; Poller W
    Gene Ther; 2007 Jun; 14(12):960-71. PubMed ID: 17377597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver.
    Au T; Thorne S; Korn WM; Sze D; Kirn D; Reid TR
    Cancer Gene Ther; 2007 Feb; 14(2):139-50. PubMed ID: 17139321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PED/PEA-15 modulates coxsackievirus-adenovirus receptor expression and adenoviral infectivity via ERK-mediated signals in glioma cells.
    Botta G; Perruolo G; Libertini S; Cassese A; Abagnale A; Beguinot F; Formisano P; Portella G
    Hum Gene Ther; 2010 Sep; 21(9):1067-76. PubMed ID: 20406097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer gene therapy with oncolytic adenoviruses.
    Guse K; Hemminki A
    J BUON; 2009 Sep; 14 Suppl 1():S7-15. PubMed ID: 19785073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.
    Galanis E; Okuno SH; Nascimento AG; Lewis BD; Lee RA; Oliveira AM; Sloan JA; Atherton P; Edmonson JH; Erlichman C; Randlev B; Wang Q; Freeman S; Rubin J
    Gene Ther; 2005 Mar; 12(5):437-45. PubMed ID: 15647767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells.
    Fechner H; Wang X; Wang H; Jansen A; Pauschinger M; Scherübl H; Bergelson JM; Schultheiss HP; Poller W
    Gene Ther; 2000 Nov; 7(22):1954-68. PubMed ID: 11127584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.